{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T21:20:33Z","timestamp":1780521633858,"version":"3.54.1"},"reference-count":46,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Neuromuscular blocking agents (NMBAs) may induce life-threatening perioperative hypersensitivity reactions (POH). In addition to the known IgE-dependent allergic background, a mechanism dependent on Mas-Related G Protein-Coupled Receptor-X2 (MRGPRX2) on mast cells has been postulated. This does not explain why NMBA-induced POH is sporadic and only occurs in some patients. We hypothesised that this phenomenon depends on single nucleotide polymorphisms (SNPs) in MRGPRX2 that enhance the response to NMBA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The protein coding sequence of the MRGPRX2 gene was sequenced in 31 patients with NMBA-induced POH and 42 controls. Medical history and skin tests were used to diagnose patients. Based on basophil activation test (BAT) and specific IgE, patients were classified as having a history of IgE-mediated or likely MRGPRX2-mediated reactions. Severity of POH was defined according to a commonly accepted scale. Molecular dynamics simulations were conducted to assess the functional and structural effects of the SNPs.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The most common causative drugs were rocuronium (n = 17) and atracurium (n = 7), the others were cisatracurium, vecuronium, suxamethonium (n = 2 each) and pipecuronium (n = 1). We detected one missense SNP: N62S, present in 38.7% of the study group and in 45.2% of the controls. Prevalence of this SNP in patients was not dependent on causative drug, BAT and sIgE results, or severity of POH or its skin manifestations. Analysis of root mean square deviation and fluctuation plots showed no significant differences between wild-type and N62S variants.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>SNPs detected within the protein coding sequence of the MRGPRX2 gene were not risk factor in NMBA-induced POH, regardless of the clinical characteristics of the patients and the causative drug in question.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1655722","type":"journal-article","created":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T05:30:44Z","timestamp":1756704644000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["The prevalence of genetic variants of the Mas-related G-protein-coupled receptor X2 in patients does not explain perioperative hypersensitivity reactions to neuromuscular blocking agents"],"prefix":"10.3389","volume":"16","author":[{"given":"Alicja","family":"Dziadowiec","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Kwitniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kopac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Rybka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lenka","family":"Sedlackova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Srotova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wojciech","family":"Dyga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Koren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Gluck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radoslaw","family":"Kitel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grzegorz","family":"Porebski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"B2","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1046\/j.0105-4538.2001.00001.x-i8","article-title":"General considerations for skin test procedures in the diagnosis of drug hypersensitivity","volume":"57","author":"Brockow","year":"2002","journal-title":"Allergy"},{"key":"B3","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.tips.2023.02.002","article-title":"The structure, function, and pharmacology of MRGPRs","volume":"44","author":"Cao","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"B4","volume-title":"Cryo EM structure of Gi coupled MRGPRX2 with small molecule agonist (R) zinc 3573","author":"Cao","year":""},{"key":"B5","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41586-021-04126-6","article-title":"Structure, function and pharmacology of human itch GPCRs","volume":"600","author":"Cao","year":"","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1709","DOI":"10.1053\/j.gastro.2020.12.076","article-title":"Inflamed ulcerative colitis regions associated with MRGPRX2 mediated mast cell degranulation and cell activation modules, defining a new therapeutic target","volume":"160","author":"Chen","year":"2021","journal-title":"Gastroenterology"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.3390\/ijms20215247","article-title":"Identification of gain and loss of function missense variants in MRGPRX2\u2019s transmembrane and intracellular domains for mast cell activation by substance P","volume":"20","author":"Chompunud Na Ayudhya","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"B8","doi-asserted-by":"publisher","first-page":"156","DOI":"10.3390\/cells10010156","article-title":"MRGPRX2 activation by rocuronium: insights from studies with human skin mast cells and missense variants","volume":"10","author":"Chompunud Na Ayudhya","year":"2021","journal-title":"Cells"},{"key":"B9","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1097\/RLI.0000000000000644","article-title":"HLA DRB1*15:02 is associated with iodinated contrast media related anaphylaxis","volume":"55","author":"Chung","year":"2020","journal-title":"Invest. Radiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1097\/EJA.0000000000001765","article-title":"Neuromuscular blocking agent induced hypersensitivity reaction exploration: an update","volume":"40","author":"Dejoux","year":"2023","journal-title":"Eur. J. Anaesthesiol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"100759","DOI":"10.1016\/j.waojou.2023.100759","article-title":"A quarter of a century fundamental and translational research in perioperative hypersensitivity and anaphylaxis at the Antwerp university hospital, a Belgian centre of excellence of the world allergy organization","volume":"16","author":"Ebo","year":"2023","journal-title":"World Allergy Organ. J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.2217\/14622416.9.10.1543","article-title":"Carbamazepine, HLA B*1502 and risk of stevens johnson syndrome and toxic epidermal necrolysis: US FDA recommendations","volume":"9","author":"Ferrell","year":"2008","journal-title":"Pharmacogenomics"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1016\/j.bja.2019.04.044","article-title":"Management of suspected immediate perioperative allergic reactions: an international overview and consensus recommendations","volume":"123","author":"Garvey","year":"","journal-title":"Br. J. Anaesth."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1872","DOI":"10.1111\/all.13820","article-title":"An EAACI position paper on the investigation of perioperative immediate hypersensitivity reactions","volume":"74","author":"Garvey","year":"","journal-title":"Allergy"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3981","DOI":"10.1172\/JCI85538","article-title":"Different activation signals induce distinct mast cell degranulation strategies","volume":"126","author":"Gaudenzio","year":"2016","journal-title":"J. Clin. Invest."},{"key":"B16","first-page":"98","article-title":"MDAnalysis: a python package for the rapid analysis of molecular dynamics simulations","author":"Gowers","year":"2016"},{"key":"B17","doi-asserted-by":"publisher","first-page":"6650","DOI":"10.1038\/s41598-022-10549-6","article-title":"Determination of key residues in MRGPRX2 to enhance pseudo allergic reactions induced by fluoroquinolones","volume":"12","author":"Hamamura Yasuno","year":"2022","journal-title":"Sci. Rep."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1859","DOI":"10.1002\/jcc.20945","article-title":"CHARMM GUI: a web based graphical user interface for CHARMM","volume":"29","author":"Jo","year":"2008","journal-title":"J. Comput. Chem."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1401604","DOI":"10.3389\/fgene.2024.1401604","article-title":"Editorial: the impact of the human genome on interindividual variability in drug response","volume":"15","author":"Kassogue","year":"2024","journal-title":"Front. Genet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.1016\/j.jaip.2021.04.045","article-title":"Biomarkers of the severity of honeybee sting reactions and the severity and threshold of systemic adverse events during immunotherapy","volume":"9","author":"Kopa\u010d","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B21","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/nchembio.2334","article-title":"In silico design of novel probes for the atypical opioid receptor MRGPRX2","volume":"13","author":"Lansu","year":"2017","journal-title":"Nat. Chem. Biol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1021\/acs.jctc.5b00935","article-title":"CHARMM GUI input generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM\/OpenMM simulations using the CHARMM36 additive force field","volume":"12","author":"Lee","year":"2016","journal-title":"J. Chem. Theory Comput."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.jid.2024.10.593","article-title":"Intrinsic regulatory mechanisms protect human skin mast cells from excessive MRGPRX2 activation: paucity in LAD2 (laboratory of allergic diseases 2) cells contributes to hyperresponsiveness of the mast cell line","volume":"145","author":"Li","year":"2025","journal-title":"J. Invest Dermatol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/all.15957","article-title":"Flow-based basophil activation test in immediate drug hypersensitivity. An EAACI task force position paper","volume":"79","author":"Mayorga","year":"2023","journal-title":"An EAACI task force position Pap. Allergy"},{"key":"B25","doi-asserted-by":"publisher","first-page":"676354","DOI":"10.3389\/fimmu.2021.676354","article-title":"MRGPRX2 and adverse drug reactions","volume":"12","author":"McNeil","year":"2021","journal-title":"Front. Immunol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1038\/nature14022","article-title":"Identification of a mast cell specific receptor crucial for pseudo allergic drug reactions","volume":"519","author":"McNeil","year":"2015","journal-title":"Nature"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1111\/all.13765","article-title":"Immune pathomechanism and classification of drug hypersensitivity","volume":"74","author":"Pichler","year":"2019","journal-title":"Allergy"},{"key":"B28","doi-asserted-by":"publisher","first-page":"3027","DOI":"10.3389\/fimmu.2018.03027","article-title":"Mas related G protein coupled receptor X2 (MRGPRX2) in drug hypersensitivity reactions","volume":"9","author":"Porebski","year":"2018","journal-title":"Front. Immunol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"100854","DOI":"10.1016\/j.waojou.2023.100854","article-title":"Clinical variables and genetic variants associated with perioperative anaphylaxis in Chinese Han population: a pilot study","volume":"17","author":"Qi","year":"2023","journal-title":"World Allergy Organ. J."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1111\/cea.70068","article-title":"Variants of the MRGPRX2 gene found in patients with hypersensitivity to quinolones and vancomycin show amplified and drug specific activation responses in vitro","author":"Quan","year":"2025","journal-title":"Clin. Exp. Allergy"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1726","DOI":"10.1016\/j.jaci.2017.05.046","article-title":"A single amino acid in MRGPRX2 necessary for binding and activation by pruritogens","volume":"140","author":"Reddy","year":"2017","journal-title":"J. Allergy Clin. Immunol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1016\/j.bja.2020.08.046","article-title":"Perioperative genetic screening: entering a new era","volume":"125","author":"Riazi","year":"2020","journal-title":"Br. J. Anaesth."},{"key":"B33","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American college of medical genetics and genomics and the association for molecular pathology","volume":"17","author":"Richards","year":"2015","journal-title":"Genet. Med."},{"key":"B34","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.jaip.2022.12.014","article-title":"Allergenic and mas related G protein coupled receptor X2 activating properties of drugs: resolving the two","volume":"11","author":"Sabato","year":"2023","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B35","doi-asserted-by":"publisher","first-page":"320","DOI":"10.2478\/jtim-2023-0120","article-title":"Could unpublishing negative results be harmful to the general public?","volume":"11","author":"Sak","year":"2023","journal-title":"J. Transl. Int. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1747-4949.2011.00723.x","article-title":"Negative results: why do they need to be published?","volume":"7","author":"Sandercock","year":"2012","journal-title":"Int. J. Stroke"},{"key":"B37","volume-title":"The PyMOL molecular graphics system","year":"2025"},{"key":"B38","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/j.jaci.2021.02.043","article-title":"Routine KIT p.D816V screening identifies clonal mast cell disease in patients with Hymenoptera allergy regularly missed using baseline tryptase levels alone","volume":"148","author":"\u0160elb","year":"2021","journal-title":"J. Allergy Clin. Immunol."},{"key":"B39","doi-asserted-by":"publisher","first-page":"e446","DOI":"10.1016\/j.bja.2020.05.046","article-title":"Association between mutated mas related G protein\u2013coupled receptor X2 and rocuronium induced intraoperative anaphylaxis","volume":"125","author":"Suzuki","year":"2020","journal-title":"Br. J. Anaesth."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e117","DOI":"10.1016\/j.bja.2019.01.002","article-title":"In vitro diagnostic tests for perioperative hypersensitivity, a narrative review: potential, limitations, and perspectives","volume":"123","author":"Takazawa","year":"2019","journal-title":"Br. J. Anaesth."},{"key":"B41","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12952-015-0033-9","article-title":"Negative results: negative perceptions limit their potential for increasing reproducibility","volume":"14","author":"Teixeira Silva","year":"2015","journal-title":"J. Negat. Results Biomed."},{"key":"B42","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jen.2017.03.020","article-title":"Giving the complete picture: why publishing negative results is important","volume":"43","author":"Wolf","year":"2017","journal-title":"J. Emerg. Nurs."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1002\/jcc.23702","article-title":"CHARMM GUI membrane builder toward realistic biological membrane simulations","volume":"35","author":"Wu","year":"2014","journal-title":"J. Comput. Chem."},{"key":"B44","doi-asserted-by":"publisher","first-page":"997389","DOI":"10.3389\/fimmu.2022.997389","article-title":"Biological screening of a unique drug library targeting MRGPRX2","volume":"13","author":"Yang","year":"2022","journal-title":"Front. Immunol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1186\/1471-2105-13-134","article-title":"Primer BLAST: a tool to design target specific primers for polymerase chain reaction","volume":"13","author":"Ye","year":"2012","journal-title":"BMC Bioinforma."},{"key":"B46","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.bja.2021.09.020","article-title":"Epidemiology of suspected life threatening perioperative anaphylaxis: a cross sectional multicentre study in China","volume":"128","author":"Zhang","year":"2022","journal-title":"Br. J. Anaesth."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1655722\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T05:30:45Z","timestamp":1756704645000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1655722\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,1]]},"references-count":46,"alternative-id":["10.3389\/fphar.2025.1655722"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1655722","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,1]]},"article-number":"1655722"}}